Vv. Mclaughlin et al., Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: A case series, ANN INT MED, 130(9), 1999, pp. 740-743
Citations number
20
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Background: Treatment of patients with secondary pulmonary hypertension has
been unsatisfactory.
Objective: To describe exercise capacity, functional class, and hemodynamic
variables after long-term intravenous infusion of prostacyclin in patients
with secondary pulmonary hypertension.
Design: Case series.
Setting: Academic referral center.
Patients: 33 patients with secondary, precapillary pulmonary hypertension (
New York Heart Association class III or IV).
Intervention: Continuous intravenous prostacyclin administered by portable
infusion pump on a compassionate-use basis. Measurements: Functional class,
treadmill time, and hemodynamic variables.
Results: Patients were followed for an average of 12.7 +/- 5.6 months. Exer
cise tolerance and New York Heart Association class improved in each patien
t. The duration of treadmill exercise increased from 186 seconds to 491 sec
onds, an increase of 305 seconds (95% CI, 194 to 417 seconds; P < 0.001). M
ean pulmonary artery pressure decreased from 60 mm Hg to 46 mm Hg. a decrea
se of 14 mm Hg (Cl, 9 to 19 mm Hg; P < 0.001). Cardiac output increased fro
m 3.90 L/min to 6.30 L/min, an increase of 2.40 L/min (CI, 1.56 to 3.25 L/m
in; P < 0.001). The pulmonary vascular resistance decreased from 1143 dynes
. s/cm(5) to 575 dynes . s/cm(5), a decrease of 567 dynes s/cm(5) (CI, 407
to 727 dynes . s/cm(5); P < 0.001). Patients with collagen vascular diseas
e, congenital heart disease, and portopulmonary hypertension were analyzed
with other patients and separately. All groups had a statistically signific
ant reduction in mean pulmonary artery pressure and a statistically signifi
cant increase in cardiac output.
Conclusion: Intravenous prostacyclin may be effective in the treatment of p
atients with certain types of secondary pulmonary hypertension.